Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their target price on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, March 4th.

Aethlon Medical Stock Down 9.5 %

Shares of AEMD stock opened at $1.36 on Friday. Aethlon Medical has a 52-week low of $1.33 and a 52-week high of $5.00. The company’s 50 day moving average is $1.64 and its 200 day moving average is $1.75. The firm has a market cap of $3.56 million, a price-to-earnings ratio of -0.27 and a beta of 1.88.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). Analysts anticipate that Aethlon Medical will post -4.98 EPS for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.